Back to top
more

Better trading starts here.

Brokerage Reports

Research for APLS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Apellis Pharmaceuticals, Inc. [APLS]

Reports for Purchase

Showing records 101 - 120 ( 291 total )

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

02/17/2023

Daily Note

Pages: 4

Syfovre (pegcetacoplan) Approved - Now What Will We Debate About?

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 5.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

01/27/2023

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

01/25/2023

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

01/23/2023

Daily Note

Pages: 36

Biotechnology- 4Q22 Commercial Biotech Preview: A New Hope

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

01/20/2023

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

01/17/2023

Industry Report

Pages: 9

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

12/22/2022

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

12/19/2022

Daily Note

Pages: 3

Apellis Starts Countdown For Pegcetacoplan Decision in Europe; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

12/02/2022

Industry Report

Pages: 5

Biotechnology Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

11/22/2022

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

11/18/2022

Daily Note

Pages: 4

With 24-Month Data Submitted, PDUFA Shifts and Still No AdCom For Pegcetacoplan

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 5.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

11/08/2022

Company Report

Pages: 8

Will They or Won''t They? Pegcetacoplan Review Overhang Likely to Persist

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

11/08/2022

Company Report

Pages: 5

Pegcetacoplan NDA Review Looks Fine to Us; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

11/04/2022

Daily Note

Pages: 25

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

11/04/2022

Daily Note

Pages: 3

Slight Change of Plans For Pecetacoplan Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

11/03/2022

Daily Note

Pages: 4

Talk About A Curve Ball - APLS Pegcetacoplan PDUFA Delayed

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 5.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

10/13/2022

Daily Note

Pages: 38

3Q22 Commercial Biotech Preview: Regulatory Catalysts Likely The Main Event

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

10/13/2022

Daily Note

Pages: 17

Biotechnology- Will Capacity Impact a GA Drug Launch? Closer Look with Physician Survey

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

10/07/2022

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Apellis Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

10/06/2022

Industry Report

Pages: 6

Retina In Focus; Takeaways from AAO

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party